Study of embryotoxic effects of intranasally administred desloratadine on laboratory animals.
DOI:
https://doi.org/10.26641/2307-0404.2017.1.101437Keywords:
embryotoxicity, intranasal administration, desloratadineAbstract
The study was conducted to detect possible changes in embryogenesis and negative effects of third generation antihistamine – desloratadine – after intranasal administration of 1.3 mg/m3 and 13.0 mg/m3 of the substance to laboratory animals during their prenatal period. In these circumstances, desloratadine does not cause any significant changes of embryogenesis parameters. Macroscopic examination of the fetus and placenta in animals of experimental groups did not reveal any pathology or physiological deviations from the norm. 13.0 mg/m3 concentration of the drug caused a decrease in the weight of embryos in comparison with control group of animals and physiological data, despite a well developed, without visible pathology, placenta. This necessitates an in-depth study of possible teratogenic effects of intranasally administred desloratadine to laboratory animals.
References
Belousov YuB, Leonova MV. [Clinical pharmacology of drugs during pregnancy, prenatal and postnatal periods]. Farmateka. 2002;6:22-27. Russian.
Glushhenko AV. [The analytical review of modern antiallergic preparations]. Ukranskij Medychnyj al'manah. 2013;3:187-90. Russian.
Experimental study of embryotoxical action of drugs (guidelines)]. Кiev, 2000;40. Ukrainian.
Zambrzhitskiy ОN, Batsukova NL. [Occupational Health in pharmacy organizations and the pharmaceutical industry enterprises: a training handbook]. Minsk, BGMU, 2014;52. Russian.
Trakhtenberg IM, Sova RE, Sheftel' VO, Onikienko FA. [The rules in toxicology problem (modern concepts and methodological approaches, the basic parameters and constants)]. Moskva, "Medicina", 1991;203. Russian.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Medical Perspectives
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.